PALM BEACH GARDENS, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before th ...

PALM BEACH GARDENS, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced management will participate in the upcoming 24th Annual Needham Virtual Healthcare Conference. Management will be presenting on Tuesday, April 8, 2025 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time. A live webcast of the event, as well as an archived recording will be available on ZimVie’s investor website at investor.zimvie.com. About ZimVieZimVie ...

PALM BEACH GARDENS, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced upcoming changes to the Company's Board of Directors, including: Non-Executive Chair David King will not stand for reelection as a director upon the expiration of his current term at the Company's annual meeting of shareholders on May 7, 2025.President and CEO Vafa Jamali will be appointed Chairman of the Board effective as of May 7, 2025.Direc ...

Dentsply Sirona XRAY and ZimVie Inc. ZIMV show below-market growth and have no meaningful upside, according Needham analysts.What Happened: Needham downgraded the two dental companies to Hold.ZimVie reported adjusted EPS of 27 cents, beating the consensus of 26 cents. The company’s sales of $111.52 million fell below the consensus of $113.4 million.Dentsply Sirona, meanwhile, reported fourth-quarter adjusted earnings per share of 26 cents. It missed the street view of 43 cents. Quarterly sales of $905 milli ...

ZimVie Inc. (NASDAQ:ZIMV) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Vafa Jamali - President & Chief Executive Officer Richard Heppenstall - Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Kevin Caliendo - UBS William McMahon - Barclays Operator Good afternoon and welcome to ZimVie's Fourth Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode. We'll be facili ...

A Global Dental Leader February 2025 1 Forward-Looking Statements and Non-GAAP Measures Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions, strategies, or prospects. We generally use the words "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides, ...

Pricing and Financial Pressures - The company is facing pricing pressures due to cost containment measures in the U.S. and other countries, including a volume-based procurement program in China that resulted in unsuccessful bids[96] - Group purchasing organizations are negotiating pricing arrangements, which may limit the company's ability to sell products to affiliated members if not selected[98] - The company has experienced downward pressure on product pricing and other effects of healthcare reform in international markets, which could adversely affect its financial condition and cash flows[99] - Inflation has increased the overall cost structure, potentially affecting liquidity and financial condition[120] - A 10% price change in raw material commodities would not have a material effect on the company's consolidated financial position, results of operations, or cash flows[260] Debt and Financial Obligations - The company incurred $595.0 million in floating rate indebtedness and prepaid $275.0 million on the term loan, with $221.9 million outstanding as of December 31, 2024[108] - The company has $221.9 million of floating rate debt, and a hypothetical 100 basis points increase in SOFR would raise annual interest expense by $2.2 million[261] - The company does not expect to pay cash dividends for the foreseeable future, as it intends to retain future earnings for business operations and expansion[169] Inventory and Supply Chain Risks - The company is exposed to risks of excess and obsolete inventory, which may adversely impact cash flow and liquidity[116] - The company has entered into supply contracts for raw materials with terms of 12 to 24 months to mitigate commodity price fluctuations[260] International Operations and Currency Risks - Approximately 41% of the company's net sales in 2024 were derived from international markets, indicating a significant reliance on global operations[124] - A significant portion of foreign revenues is generated in Europe and Japan, making the company vulnerable to currency exchange rate fluctuations[117] - The company is exposed to foreign currency exchange rate risks primarily with Euros, Japanese Yen, Canadian Dollars, and Swiss Francs, and manages this risk through derivative financial instruments[259] Regulatory and Compliance Challenges - The company is subject to income taxes in the U.S. and various foreign jurisdictions, with ongoing audits that could materially affect financial statements[121] - The company is subject to stringent FDA regulations for medical devices, which can delay product approvals and impact financial results[131] - Compliance with the EU MDR, effective since May 2021, requires significant expenses and could delay marketing approvals for products in the EU[135] - The company is exposed to healthcare fraud and abuse laws, which could result in substantial penalties and affect business operations[137] - Data privacy and security laws, including the EU GDPR, impose significant compliance costs and potential liabilities for the company[142] - Compliance with new or changing laws related to data protection could result in substantial civil and/or criminal penalties, adversely impacting the business and financial condition[144] Operational and Technological Risks - Implementation of new enterprise resource planning (ERP) systems has caused disruptions, impacting operating results in 2022, with potential for similar issues in 2025 and beyond[100] - The company is increasingly dependent on sophisticated information technology, and failure to maintain or protect information systems could adversely affect operations[146] - Cyber-attack attempts are becoming more frequent and sophisticated, posing risks to business operations and reputation[149] Legal and Environmental Risks - The company bears the risk of warranty claims on products, which could exceed warranty reserves and harm financial condition[150] - Intellectual property rights are crucial for the company, and failure to protect these rights could result in significant monetary damages and impact product sales[151] - The company is involved in various legal proceedings that could result in adverse outcomes, potentially harming financial results[154] - The business involves the use of hazardous materials, and compliance with environmental laws may incur significant costs and restrict operations[156] - Climate change poses risks to operations from natural disasters, which could increase operational costs and impact supply chains[157] Market and Stock Performance - The market price of the company's common stock may be volatile, influenced by various factors including operating results and market conditions[167] - Analysts' research and reports significantly influence the trading market for the company's common stock, and unfavorable reports could lead to a decline in stock price[164] - The company has significant credit risk concentrations in public and private hospitals and dental practices, particularly in Europe, which are subject to government budget constraints[263] Foreign Regulatory and Trade Risks - The company faces risks from changes in foreign regulatory requirements, currency fluctuations, and trade barriers that could increase operating costs[125] - Zimmer Biomet may require indemnification for additional taxes resulting from acquisitions, which could materially impact the company's financial results[162]

Exhibit 99.1 ZimVie Reports Fourth Quarter and Full Year 2024 Financial Results PALM BEACH GARDENS, Florida, February 26, 2025 (GLOBE NEWSWIRE) – ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter and year ended December 31, 2024. Management will host a corresponding conference call today, February 26, 2025, at 4:30 p.m. Eastern Time. "2024 was a transformational year for ZimVie. We became a pure play dental companyand reshaped ou ...

FY2024 Third Party Net Sales from Continuing Operations of $449.7 millionFY2024 Net Loss from Continuing Operations of $(33.8) million; Net Loss margin of (7.5%) FY2024 Adjusted EBITDA[1] from Continuing Operations of $60.0 million; Adjusted EBITDA[1] margin of 13.3%FY2024 GAAP diluted EPS from Continuing Operations of $(1.23) and adjusted diluted EPS[1] of $0.62 PALM BEACH GARDENS, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today ...

Core Viewpoint - ZimVie Inc. will report its financial results for Q4 and full-year 2024 on February 26, 2025, after market close, followed by a conference call at 4:30 p.m. Eastern Time [1]. Company Overview - ZimVie is a global leader in the dental market, focusing on developing, manufacturing, and delivering a comprehensive portfolio of products for dental tooth replacement and restoration [2]. - The company is headquartered in Palm Beach Gardens, Florida, and operates additional facilities worldwide, aiming to enhance smiles, function, and confidence through its dental solutions [2]. - ZimVie offers a range of products including dental implants, biomaterials, and digital workflow solutions, and is committed to advancing clinical science and technology in the dental field [2].